Novo-Nordisk stock holds firm as 2025 profit and sales stay high
Published on 07/23/2026 at 07:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S (ISIN DK0062498333) is still trading against a backdrop of DKK 290.4 billion in sales for 2025 and DKK 128.3 billion in operating profit for 2025, two figures that frame the stock even on a quiet tape. The company also reported gross margin of 84.4% for 2025, underlining how much pricing power and scale still matter for Novo-Nordisk stock.
DKK 290.4 billion sales
Sales rose to DKK 290.4 billion in 2025 from DKK 232.3 billion in 2024, a year-on-year increase of 25.0% that gives investors a clear reference point for the latest trading narrative. Operating profit increased to DKK 128.3 billion in 2025 from DKK 102.6 billion in 2024, while net profit rose to DKK 101.0 billion from DKK 83.7 billion over the same period.
The comparison matters because it shows that the company entered 2026 with a high absolute earnings base rather than a flat operating profile. Gross margin of 84.4% in 2025 also shows that the business still converts a large share of revenue into profit.
Profit growth stayed intact
Reported diluted earnings per share reached DKK 22.70 in 2025, up from DKK 18.69 in 2024, which is a 21.5% increase. Free cash flow came in at DKK 70.7 billion in 2025, after DKK 52.0 billion in 2024, giving the balance-sheet story another dated metric that supports the equity case.
For the market, those figures are more useful than broad labels such as 'growth' or 'scale'. They define the level Novo-Nordisk stock is priced against, especially when the next visible catalyst is a new quarterly update rather than a structural change in the business model.
Wegovy still matters
Wegovy remains the clearest representative product for the market story around Novo Nordisk, because obesity treatment demand has been central to the company’s expansion. In 2025, the company also reported that sales in its obesity care area remained a key driver within the broader portfolio.
That product mix matters because a stock priced on expectations needs both growth and margin durability. Novo Nordisk is not just a single-product story, but Wegovy is still the name investors use to anchor the debate.
Copenhagen quote context
As a listed Danish company, Novo Nordisk trades in Copenhagen, and that venue remains the cleanest market reference for the shares. The stock is still measured against the company’s 2025 revenue of DKK 290.4 billion, operating profit of DKK 128.3 billion, and EPS of DKK 22.70, all of which are visible and dated in the latest annual reporting context.
For readers tracking the name, those are the numbers that matter most right now: sales up 25.0%, operating profit up 25.0%, and free cash flow at DKK 70.7 billion in 2025. That combination gives Novo Nordisk stock a high earnings base heading into the next reporting cycle.
Read more on Novo Nordisk
The latest annual reporting context is the best way to track how Novo Nordisk translates obesity and diabetes demand into revenue, margin, and cash flow. That remains more useful than broad company background when judging the share.
Company facts
Company: Novo Nordisk A/S
ISIN: DK0062498333
Trading venue: Copenhagen
Sector / Industry: Health Care / Pharmaceuticals
Index membership: OMX Copenhagen 25
Market capitalization: not included
Social search
Search interest around Novo Nordisk stock can be checked across major social platforms and video results for the company name.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
